Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: Final results of a phase II trial

European Journal of Endocrinology

Volumn 167, Issue 5, 2012, Pages 643-650

  Schneider, T C ^a   Abdulrahman, R M ^a   Corssmit, E P ^a   Morreau, H ^a   Smit, J W A ^a   Kapiteijn, E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANGIONEUROTIC EDEMA; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DIFFERENTIATED THYROID CANCER; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEART INFARCTION; HEMATURIA; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPONATREMIA; HYPOPARATHYROIDISM; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; LEUKOPENIA; LONG TERM CARE; LUNG SMALL CELL CANCER; MALAISE; MALE; MUCOSA INFLAMMATION; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMOTHORAX; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIOIODINATION; SIDE EFFECT; SYNDROME DELINEATION; THROMBOCYTOPENIA; TONGUE CARCINOMA; WEIGHT REDUCTION;

ADENOCARCINOMA, FOLLICULAR; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA; CARCINOMA, PAPILLARY; CARCINOMA, PAPILLARY, FOLLICULAR; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IODINE RADIOISOTOPES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PYRIDINES; THYROGLOBULIN; THYROID NEOPLASMS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84867527699     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0405     Document Type: Article

References (32)

1. American Cancer Society. Cancer Facts & Figures 2010. Atlanta: American Cancer Society; 2010.
2. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase.
3. Schlumberger M. Management of refractory thyroid cancers. Annales d'Endocrinologie 2011 72 149-157. (doi:10.1016/j.ando.2011.03.020)
4. Schlumberger MJ. Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. Journal of Endocrinological Investigation 1999 22 3-7.
5. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM & American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006 16 109-142. (doi:10.1089/thy. 2006.16.109)
6. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW,WiersingaW & European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology 2006 154 787-803. (doi:10.1530/eje.1.02158)
7. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B & Griffin A. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Annals of Surgery 2007 246 466-470. (doi:10.1097/SLA. 0b013e318148563d)
8. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M & Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocrine-Related Cancer 2006 13 257-269. (doi:10.1677/erc.1.01119)
9. Segev DL, Umbricht C & Zeiger MA. Molecular pathogenesis of thyroid cancer. Surgical Oncology 2003 12 69-90. (doi:10.1016/S0960-7404(03)00037-9)
10. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE & Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Research 2003 63 1454-1457. (Pubitemid 36373628)
11. Espinosa AV, Porchia L & Ringel MD. Targeting BRAF in thyroid cancer. British Journal of Cancer 2007 96 16-20. (doi:10.1038/sj.bjc.6603520)
12. Hicklin DJ & Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of Clinical Oncology 2005 3 1011-1027. (Pubitemid 46202320)
13. Bible KC, SMallridge RC & Maples WJ. Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers. Journal of Clinical Oncology 2009 27 3521.
14. Bible KC, Suman VJ & Molina JR. Efficacy of pazopanib in rapidly progressive radioiodine-refractory metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncology 2010 11 962-972. (doi:10.1016/S1470-2045(10)70203-5)
15. Ivan M, Bond JA & Prat M. Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 1997 14 2417-2423. (doi:10.1038/sj.onc.1201083)
16. Cabanillas ME, Brose MS & Ramies DA. Anti-tumor Activity Observed in a Cohort of Patients (pts) with Differentiated Thyroid Cancer (DTC) in a Phase 1 Study of Cabozantinib (XL184). American Thyroid Association, 81st Annual Meeting, 10/2011.
17. Matsui J, Yamamoto Y & Funahashi Y. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. International Journal of Cancer 2008 122 664-671. (doi:10.1002/ijc.23131)
18. Matsui J, Funahashi Y & Uenaka T. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 2008 14 5459-5465. (doi:10.1158/1078-0432.CCR-07-5270)
19. Sherman SI, Jarzab B & Cabanillas ME. Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology.
20. Rajoria S, Suriano R & George AL. Molecular target based combinational therapeutic approaches in thyroid cancer. Journal of Translational Medicine 2012 10 81. (doi:10.1186/1479-5876-10-81)
21. Keefe SM, Troxel AB, Rhee S, Puttaswamy K, O'Dwyer PJ, Loevner LA, Mandel SJ & Brose MS. Phase II trial of sorafenib in patients with advanced thyroid cancer. Journal of Clinical Oncology 2011 29.
22. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ & Brose MS. Phase II trial of sorafenib in advanced thyroid cancer. Journal of Clinical Oncology 2008 26 4714-4719. (doi:10.1200/JCO.2008.16.3279)
23. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M & Shah MH. Phase II trial of sorafenib in metastatic thyroid cancer. Journal of Clinical Oncology 2009 27 1675-1684. (doi:10.1200/JCO.2008.18.2717)
24. Loh Ho A, Leboeuf R & Grewal RK. Reacquisition of RAI uptake in RAI-refractory metastatic thyroid cancers by pretreatment with the MEK inhibitor selumetinib. Journal of Clinical Oncology 2012 30 (suppl; abstract 5509).
25. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, Weijers K, Pereira AM, Huijberts M, Kapiteijn E, Romijn JA & Smit JW. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. European Journal of Endocrinology 2009 161 923-931. (doi:10.1530/EJE-09-0702)
26. Knauf JA & Fagin JA. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Current Opinion in Cell Biology 2009 21 296-303. (doi:10.1016/j.ceb.2009.01.013)
27. Xing J, Liu R, Xing M & Trink B. The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). Biochemical and Biophysical Research Communications 2011 404 958-962. (doi:10.1016/j.bbrc.2010.12.088)
28. Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, Harrington KJ, Marais R & Nutting CM. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. European Journal of Endocrinology 2011 165 315-322. (doi:10.1530/EJE-11-0129)
29. Hoftijzer H, Kapiteijn E, Schneider TC, Hovens GC, Morreau H, Gelderblom H & Smit JWA. Tyrosine kinase inhibitors in differentiated thyroid carcinoma: a review of the clinical evidence. Clinical Investigation 2011 1 241-252. (doi:10.4155/cli.10.29)
30. Yang L, Shi L & Fu Q. Efficacy and safety of sorafenib in advanced renal cell carcinoma patients: results from a long-term study. Oncology Letters 2012 3 935-939.
31. Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, Rizzo S, Venditti O, Frezza AM, Caraglia M, Colucci G, Del Prete S & Tonini G. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010 15 85-92. (doi:10.1634/theoncologist.2009-0143)
32. Kapiteijn E, Schneider TC, Morreau H, Gelderblom H, Nortier JW& Smit JW. New treatment modalities in advanced thyroid cancer. Annals of Oncology 2012 23 10-18. (doi:10.1093/annonc/mdr117)